ACI can be administered in two ways: (i) lymphokine-activated killer (LAK) cell therapy, in which cells are extracted from patients and cultured in vitro with high concentrations of IL-2 in peripheral blood leukocytes before being injected back into the cancer site; and (ii) tumour-infiltrating lymphocyte (TIL) therapy, in which cells are extracted from lymphocytes recovered from the patient with cancer and incubated with high concentrations of IL-2 before being injected back into the patient. This evidence concerns the gene IL2 and cancer.